Intest Stock Price, News & Analysis

inTEST Corporation (NYSE American: INTT) will release its first quarter 2023 financial results on May 5, 2023, before the market opens. A conference call will be held at 8:30 a.m. ET on the same day to discuss the results and the company’s strategies and outlook. The call will include a question-and-answer session. Investors can access the conference call via phone or the company’s website. A replay will be available from 11:30 a.m. ET that day until May 12, 2023. inTEST specializes in test and process solutions for various sectors including automotive, defense, and semiconductor manufacturing, leveraging a strong engineering background to drive growth and profitability.

inTEST Corporation (NYSE American: INTT) announced a partnership between its subsidiary, inTEST Thermal Solutions, and Stellar Scientific. This collaboration aims to distribute inTEST’s Ultra-Low Temperature (ULT) biomedical freezers, enhancing opportunities in the U.S. government market through Stellar's General Services Administration (GSA) contract. The North Sciences ULT freezers are crucial for preserving biomedical samples at -86°C, ensuring research integrity. Leaders from both companies expressed optimism about expanding their reach and offerings, particularly within the life sciences and defense sectors. This initiative aligns with inTEST's strategic focus on innovative solutions in critical temperature control.

inTEST Corporation (NYSE American: INTT) announced its participation in the Sidoti Small Cap Conference on March 23, 2023. The presentation will be led by Nick Grant, President & CEO, and Duncan Gilmour, CFO, starting at 10:00 a.m. Eastern Time. A live webcast, along with presentation materials, will be accessible on their investor relations website. inTEST specializes in innovative test and process solutions for various sectors, including automotive, defense, industrial, and semiconductor manufacturing.

inTEST Corporation (NYSE American: INTT) reported record fourth quarter revenue of $32.4 million, a 45% increase, and full year revenue of $116.8 million, up 38% compared to the prior year. Fourth quarter earnings per diluted share were $0.30, with $31.3 million in orders, marking a 3% increase. The company anticipates Q1 2023 revenue between $30 million and $32 million, and full year 2023 revenue of $125 million to $130 million. The growth was supported by strong demand in semiconductor, automotive, defense, and life sciences sectors, alongside successful integration of acquisitions.

inTEST Corporation (NYSE American: INTT) reported preliminary unaudited results for Q4 and FY 2022, highlighting a substantial revenue growth. Q4 revenue is anticipated at $32.4 million, up 44.9% from Q4 2021, while total revenue for 2022 is projected at $116.8 million, indicating a 37.6% year-over-year increase. Orders for Q4 were approximately $31.3 million, a 2.8% rise compared to the previous year, with full-year orders reaching $129.6 million, marking a 27.1% increase. CEO Nick Grant expressed optimism regarding demand and future growth strategies. A detailed earnings report is expected on March 3, 2023.

inTEST Corporation (NYSE American: INTT), a leader in innovative test and process solutions, announced participation in the Allied Global Partners Tech Conference on February 16. The company’s President & CEO, Nick Grant, and CFO, Duncan Gilmour, will be available for investor meetings. inTEST operates across diverse sectors including automotive, defense, industrial, life sciences, and semiconductor manufacturing, leveraging extensive engineering expertise to solve complex challenges. With a focus on organic growth and acquisitions, inTEST aims to expand its market reach and innovative technologies.

inTEST Corporation (NYSE American: INTT) has partnered with Traceable, an Antylia Scientific Company, to integrate its TraceableLIVE® cloud service into North Sciences Ultra-Low Temperature (ULT) biomedical freezers. This addition will enable remote monitoring of critical temperatures, enhancing sample security for medical and research labs. The freezers, capable of -86°C storage, are designed to protect samples and research integrity. This collaboration aims to provide a modern solution for researchers, ensuring peace of mind regarding sample safety.